Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets


Out-
      side
 



 
 'Ferumoxtran' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Ferumoxtran' found in 1 term [] and 2 definitions []
1 - 3 (of 3)     
Result Pages : [1]
Searchterm 'Ferumoxtran' was also found in the following service: 
spacer
News  (3)  
 
FerumoxtranInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: Ami 227, generic name: Ferumoxtran, (USPIO)
Ferumoxtran is a substance of the class of ultrasmall superparamagnetic iron oxide used as a lymph node specific contrast agent for MRI.
See also Combidex®, Sinerem® and Ultrasmall Superparamagnetic Iron Oxide.
Partner(s): Cytogen Corporation, National Cancer Institute. An approvable letter was received from the U.S. Food and Drug Administration for Combidex in June 2000. Advanced Magnetics, Inc. has submitted a complete response to the approvable letter received from the U.S. Food and Drug Administration, which was accepted by the FDA and assigned a user fee goal date of March 30, 2005. In Europe, a Dossier (the European equivalent of a NDA) was submitted by Advanced Magnetics' European partner, Guerbet SA, to the European Medicines Evaluations Agency in December 1999. (Sinerem® is the brand name for this USPIO in Europe manufactured by Guerbet, Combidex® by Advanced Magnetics for the U.S. market)
Advanced Magnetics, Inc. changed its name in July 2007 to AMAG Pharmaceuticals Inc
spacer
 
• Share the entry 'Ferumoxtran':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  Basics:
Superparamagnetic Iron Oxide–enhanced MR Imaging of Head and Neck Lymph Nodes1
Comparison of Two Superparamagnetic Viral-Sized Iron Oxide Particles Ferumoxides and Ferumoxtran-10 with a Gadolinium Chelate in Imaging Intracranial Tumors
2002   by www.ajnr.org    
  News & More:
Optimized Labelling of Human Monocytes with Iron Oxide MR Contrast Agents
Sunday, 30 November 2003   by rsna2003.rsna.org    
Ultrasmall Superparamagnetic Particles of Iron Oxide-enhanced in vivo MRI of human atherosclerotic plaques.(.pdf)
MRI Resources 
Movies - Contrast Agents - Examinations - Artifacts - MRCP - RIS
 
Combidex®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Combidex® is the brand name (same as Sinerem®) for an ultrasmall superparamagnetic iron oxide (USPIO) in the development pipeline to detect metastatic disease in lymph nodes. Metastatic lymph nodes show less uptake of this MRI contrast agent, which results in less signal decrease and allows the differentiation of normal lymph nodes from normal-sized, metastatic nodes. Combidex® has also potential to be used as a functional molecular imaging agent.
In March 2005, AMAG Pharmaceuticals Inc received an approvable letter from the U.S. Food and Drug Administration with respect to Combidex subject to certain conditions.
See also Ferumoxtran, Drug Development and Approval Process USA, Molecular Imaging and Classifications, Characteristics, etc.

Drug Information and Specification
NAME OF COMPOUND Ferumoxtran, USPIO, AMI-227
DEVELOPER AMAG Pharmaceuticals, Inc.
CENTRAL MOIETY Fe3+/Fe2+
CONTRAST EFFECT T1, predominantly T2
RELAXIVITY r1=25, r2=160, B0=0.47T, r1=23.3, r2=48.9, B0=0.47T
PHARMACOKINETIC Vascular, lymph v. hepatocyte (AG-USPIO)
OSMOLALITY
CONCENTRATION
DOSAGE 2.6 mg Fe/kg
PREPARATION Suspend in an isotonic glucose solution
INDICATION Lymph node, (MR angiography vascular, staging of RES-directed liver diseases)
DEVELOPMENT STAGE
DISTRIBUTOR
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!


spacer

• View the DATABASE results for 'Combidex®' (6).Open this link in a new window


• View the NEWS results for 'Combidex®' (1).Open this link in a new window.
 
Further Reading:
  Basics:
The demise of Combidex - Sinerem
Wednesday, 24 March 2010   by www.wellsphere.com    
  News & More:
Combidex, MRI, and identification of nodal metastases
Wednesday, 17 June 2009   by prostatecancerinfolink.net    
Superparamagnetic Iron Oxide–enhanced MR Imaging of Head and Neck Lymph Nodes1
MRI Resources 
Stimulator pool - Breast Implant - MRI Technician and Technologist Jobs - Developers - Liver Imaging - Fluorescence
 
Sinerem®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Sinerem® is the brand name (same as Combidex®) for an ultrasmall superparamagnetic iron oxide (USPIO) to detect metastatic disease in lymph nodes. Metastatic nodes show less uptake of this MRI contrast agent, which results in less signal decrease and allows the differentiation of normal lymph nodes from normal-sized, metastatic nodes.
Lymph node imaging with Sinerem® is performed 24 to 36 hours after slow infusion. Normal lymph nodes turn black post contrast, namely on T2* weighted images. Metastatic lymph nodes remain unchanged in signal intensity.
Indication and Diseases: Cancer, Imaging for diagnosis, Lymphatic disorders.
See Ferumoxtran, and Classifications, Characteristics, etc.

Guerbet decided in 2007 to withdraw its Marketing Authorisation Application (MAA) for Sinerem.


Drug Information and Specification
NAME OF COMPOUND Ferumoxtran, USPIO, AMI-227
DEVELOPER AMAG Pharmaceuticals, Inc.
CENTRAL MOIETY Fe3+/Fe2+
CONTRAST EFFECT T1, T2
RELAXIVITY r1=25, r2=160, B0=0.47T, r1=23.3, r2=48.9, B0=0.47T
PHARMACOKINETIC Vascular, lymph v. hepatocyte (AG-USPIO)
OSMOLALITY
CONCENTRATION
DOSAGE 2.6 mg Fe/kg
PREPARATION Suspend in an isotonic glucose solution
INDICATION MR angiography vascular, staging of RES-directed liver diseases, lymph nodes
DEVELOPMENT STAGE -
DISTRIBUTOR
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
spacer

• View the DATABASE results for 'Sinerem®' (6).Open this link in a new window

 
Further Reading:
  Basics:
The demise of Combidex - Sinerem
Wednesday, 24 March 2010   by www.wellsphere.com    
  News & More:
Ultrasmall Superparamagnetic Particles of Iron Oxide-enhanced in vivo MRI of human atherosclerotic plaques.(.pdf)
Searchterm 'Ferumoxtran' was also found in the following service: 
spacer
News  (3)  
 
     1 - 3 (of 3)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



The impact of TTIP/TPP on the MRI scanner market will bring :
more variety 
better scanners 
more risk 
less regulation 
cheaper scanners 
Lost in Translation 
no change at all 

Look
      Ups





Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2003 - 2016 SoftWays. All rights reserved. [ 23 January 2017]
Terms of Use | Privacy Policy | Advertising
 [last update: 2017-01-13 03:47:00]